Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

Imaging Inflammation in Alzheimer's Disease with 11C-ER176

Start: September 10, 2018
End: July 2022
Enrollment: 50

What Is This Study About?

Positron emission tomography (PET) imaging is a type of brain scanning method that allows researchers to use radioactive tracers to measure small molecules in the brain. This study will test the ability of the radioactive tracer 11C-ER176 to stick to parts of the brain where there is inflammation. Participants will undergo PET scanning and blood sampling to measure 11C-ER176. Another type of dye, florbetaben, which has been approved by the U.S. Food and Drug Administration to help diagnose Alzheimer's disease, will also be used.

Do I Qualify To Participate in This Study?

Minimum Age: 50 Years

Maximum Age: N/A

Must have:

  • Meet criteria for either a) amnestic mild cognitive impairment (MCI) or Alzheimer's disease, or b) have no cognitive impairment
  • If unable to provide informed consent, must have surrogate decision maker and be able to verbally assent to study procedures
  • Fluent in written and spoken English
  • Able to participate in all scheduled evaluations and to complete all required tests and procedures
  • Must be considered likely to comply with study protocol and have a high probability of completing the study

Must NOT have:

  • Past or present history of certain brain disorders other than MCI or Alzheimer's disease
  • Certain significant medical conditions that make study procedures unsafe, including uncontrolled epilepsy and multiple serious injuries
  • Inability to undergo magnetic resonance imaging, including metal implants, morbid obesity, and claustrophobia
  • Exposure to research-related radiation in the past year that would exceed allowable limits
  • Participation in the last year in a clinical trial for a disease-modifying Alzheimer's drug
  • Inability to have a catheter in the vein for the injection of the tracer
  • Inability to have blood drawn from veins
  • Taking anticoagulant medication (e.g., warfarin)

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.


Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: William Charles Kreisl

Source: ID: NCT03744312

An official website of the U.S. government, managed by the National Institutes on Aging at the National Institutes of Health